You are here:

1. Homepage
2. Pharmacovigilance
3. Information on Risks

EMA recommends suspension of marketing authorisation for all medicinal products containing buflomedil

The Committee for Medicinal Products on Human Use (CHMP) of the European Medicines Agency (EMA) has completed its review of the benefit/risk balance of buflomedil and has come to a negative conclusion. The EMA recommends that all marketing authorisations for medicines containing buflomedil should be suspended throughout the Member States of the EU.

risk information - full text (available in German only)